Our data demonstrate that in the absence of RIPK3, colonic inflammation was increased as was the tumor incidence and size following AOM-DSS treatment, indicating that RIPK3 has a fundamental role in inhibiting intestinal inflammation and colitis-associated CRC development. This evidence concerns the gene RIPK3 and colitis.